AUPH Aurinia Pharmaceuticals Inc
$17.25▲ +1.23%
Healthcare
Other
After hours
$17.25▲ +0.00%
Oct 27, 4:17 PM ET
Volume 494.5K
Avg Volume (10D) 828.5K
Key Metrics & Fundamentals
Market Cap
$2.30B
P/E Ratio
7.6
Div Yield
0.00%
52W Range
11.96 - 19.25
% vs 50 MA
4.95%
% vs 200 MA
10.44%
RSI-14
61.5
MACD Histogram
+0.0800
Beta (1Y vs SPY)
0.51
Free Cash Flow
$52.57M
Gross Rev
$83.22M
Gross Profit
$76.67M
EBITDA
$54.57M
COGS
$6.56M
Operating Exp
$30.32M
Operating Income
$46.34M
EBIT
$46.34M
Pretax Income
$48.79M
Net Income
$37.41M
EPS (Diluted)
0.28
Price & Volume History
Loading chart…
Recent News
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
Zacks · Oct 27, 2026 9:00 AM ET
Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company
Insider Monkey · Sep 16, 2026 1:13 AM ET
Immatics and 4 More Stocks See Action From Activist Investors
Barrons.com · Sep 4, 2026 6:59 PM ET
LB Pharmaceuticals Names Joseph Miller CFO
MT Newswires · Sep 3, 2026 8:38 AM ET
Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?
Insider Monkey · Aug 28, 2026 5:14 PM ET
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback
Simply Wall St. · Aug 20, 2026 3:11 AM ET
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain
Simply Wall St. · Aug 19, 2026 8:16 PM ET
AUPH Stock Rallies 6% After-Hours — Here’s Why
Stocktwits · Aug 19, 2026 6:15 PM ET
Aurinia Settles Patent Lawsuit With Teva; Shares Rise After Hours
MT Newswires · Aug 19, 2026 4:37 PM ET
Aurinia Settles Patent Litigation with Teva
Business Wire · Aug 19, 2026 4:05 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See AUPH's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.